Why Accounting for Our Differences Matter in Assessing Drug Value

2020-06-04T20:24:50-06:00June 4th, 2020|IVI News|

IVI’s Jennifer Bright and Amy Miller, former CEO of the Society for Women’s Health Research, explain why patient heterogeneity is crucial to consider in any value assessment method.

Read the full article here.